These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 16925946)

  • 1. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.
    Dai MS; Jin Y; Gallegos JR; Lu H
    Neoplasia; 2006 Aug; 8(8):630-44. PubMed ID: 16925946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Pirh2 in mediating the regulation of p53 and c-Myc.
    Hakem A; Bohgaki M; Lemmers B; Tai E; Salmena L; Matysiak-Zablocki E; Jung YS; Karaskova J; Kaustov L; Duan S; Madore J; Boutros P; Sheng Y; Chesi M; Bergsagel PL; Perez-Ordonez B; Mes-Masson AM; Penn L; Squire J; Chen X; Jurisica I; Arrowsmith C; Sanchez O; Benchimol S; Hakem R
    PLoS Genet; 2011 Nov; 7(11):e1002360. PubMed ID: 22125490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Yin-yang relationship between oncogene and antioncogene].
    Jia YS; Zheng JQ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jan; 29(1):72-5. PubMed ID: 19338159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.
    Hatakeyama S; Watanabe M; Fujii Y; Nakayama KI
    Cancer Res; 2005 Sep; 65(17):7874-9. PubMed ID: 16140957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.
    Chen D; Shan J; Zhu WG; Qin J; Gu W
    Nature; 2010 Mar; 464(7288):624-7. PubMed ID: 20208519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and c-myc: how does the cell balance "yin" and "yang"?
    Sachdeva M; Mo YY
    Cell Cycle; 2009 May; 8(9):1303. PubMed ID: 19342882
    [No Abstract]   [Full Text] [Related]  

  • 7. c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis.
    Feng YC; Liu XY; Teng L; Ji Q; Wu Y; Li JM; Gao W; Zhang YY; La T; Tabatabaee H; Yan XG; Jamaluddin MFB; Zhang D; Guo ST; Scott RJ; Liu T; Thorne RF; Zhang XD; Jin L
    Nat Commun; 2020 Oct; 11(1):4980. PubMed ID: 33020477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
    Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
    Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun.
    Westermarck J
    Methods Mol Biol; 2010; 647():31-6. PubMed ID: 20694659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms.
    Qi CF; Kim YS; Xiang S; Abdullaev Z; Torrey TA; Janz S; Kovalchuk AL; Sun J; Chen D; Cho WC; Gu W; Morse Iii HC
    Int J Mol Sci; 2012; 13(5):6204-6219. PubMed ID: 22754359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity.
    Zhang Q; Spears E; Boone DN; Li Z; Gregory MA; Hann SR
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):978-83. PubMed ID: 23277542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skp2 regulates Myc protein stability and activity.
    Kim SY; Herbst A; Tworkowski KA; Salghetti SE; Tansey WP
    Mol Cell; 2003 May; 11(5):1177-88. PubMed ID: 12769843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Myc-nucleophosmin-ARF network: a complex web unveiled.
    Li Z; Hann SR
    Cell Cycle; 2009 Sep; 8(17):2703-7. PubMed ID: 19652540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 ubiquitination: Mdm2 and beyond.
    Brooks CL; Gu W
    Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes alters expression of p53 and c-myc in different stages of oral oncogenesis.
    Vairaktaris E; Kalokerinos G; Goutzanis L; Spyridonidou S; Vassiliou S; Derka S; Nkenke E; Yapijakis C; Vylliotis A; Lazaris A; Patsouris E
    Anticancer Res; 2007; 27(3B):1465-73. PubMed ID: 17595763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
    Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
    J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
    Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
    Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.